<?xml version="1.0" encoding="utf-8"?>
<urlset>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/thyroid-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/stomach-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
</urlset>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/small-cell-lung-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/skin-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/rectal-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/rectal-cancer/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/prostate-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/prostate-cancer/screening</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/prostate-cancer/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/penile-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/parathyroid-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/pancreatic-islet-cell/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/pancreatic-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/non-small-cell-lung/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/non-small-cell-lung/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/myeloproliferative-neoplasm/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/myelodysplastic-myeloproliferative/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/multiple-myeloma/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/mesothelioma/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/merkel-cell/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/kaposi-sarcoma/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/hairy-cell-leukemia/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/gallbladder-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/extragonadal-germ-cell-tumors/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/screening</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/esophageal-cancer/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/colorectal-cancer/screening</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cll/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cll/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/clear-cell-renal-cell</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/clear-cell-renal-cell</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cervical-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cervical-cancer/screening</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cervical-cancer/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9306/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9306/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9242/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9242/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9160/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9154/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C9145/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C8578/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C7884/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C7709/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/c7251,c9063/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C5816,C8550,C3813/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C4967/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3997/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3330,C4348,C8388/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3270/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3247/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3174/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C3168/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C2910/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C2910/screening</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C2910/prevention</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/C114812/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/bladder-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/anal-cancer/treatment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/disulfiram</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pembrolizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/nivolumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/delta-8-tetrahydrocannabinol</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sting-agonist-mk-1454</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-cd47-monoclonal-antibody-hu5f9-g4</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/atezolizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/epacadostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/idh1-inhibitor-ag-120</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/avelumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/wee1-inhibitor-azd1775</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-lag-3-monoclonal-antibody-bms-986016</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-tigit-monoclonal-antibody-bms-986207</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ibrutinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sodium-dichloroacetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/durvalumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ribociclib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/abemaciclib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/olaparib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/docetaxel</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/capecitabine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tumor-infiltrating-lymphocyte-therapy</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/palbociclib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bevacizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/selumetinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cisplatin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/prima-1-analog-apr-246</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fgfr-inhibitor-tas-120</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/everolimus</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ipilimumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/letrozole</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/spartalizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tazemetostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/venetoclax</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alisertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/selinexor</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/daratumumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/azacitidine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/indoximod</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/8-hydroxyquinoline-sulfate-ointment</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-tim-3-monoclonal-antibody-tsr-022</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/glutaminase-inhibitor-cb-839</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/carboplatin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/paclitaxel</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/curcumin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/temozolomide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lsd1-inhibitor-gsk2879552</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/axl-inhibitor-bgb324</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/abiraterone-acetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tisagenlecleucel</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sorafenib-tosylate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/doxorubicin-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/idasanutlin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/enzalutamide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/napabucasin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/akt-inhibitor-azd5363</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/methotrexate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/chitin-oligosaccharides-supplement-t-chos</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/akterk-inhibitor-onc201</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3k-gamma-inhibitor-ipi-549</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trametinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-ox40-monoclonal-antibody</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cyclophosphamide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fermented-wheat-germ-extract</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/entinostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/imatinib-mesylate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fgfr-inhibitor-incb054828</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/brentuximab-vedotin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anastrozole</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3k-delta-inhibitor-incb050465</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tremelimumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/veliparib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trastuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tamoxifen-citrate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/egfr-inhibitor-egf816</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-cd73-monoclonal-antibody-bms-986179</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cetuximab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/adenosine-a2a-receptor-antagonist-cpi-444</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/atr-kinase-inhibitor-vx-970</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-icos-agonist-antibody-gsk3359609</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/aspirin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sapanisertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cxcr4-antagonist-bl-8040</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/neratinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alpelisib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/radium-ra-223-dichloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-ox40-antibody-bms-986178</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/egfr-inhibitor-abt-414</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gvax-pancreatic-cancer-vaccine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/boswellia-serrata-extract</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/birinapant</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pazopanib-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mdm2-inhibitor-amg-232</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-fgfr-kinase-inhibitor-bgj398</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/oxaliplatin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cobimetinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/decitabine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/capmatinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/smac-mimetic-lcl161</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gilteritinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/rituximab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ruthenium-ru-106</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/erk-inhibitor-ltt462</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ramucirumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fluorouracil</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lutetium-lu-177-dota-tate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pegylated-liposomal-doxorubicin-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trastuzumab-emtansine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/porcupine-inhibitor-wnt974</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/osimertinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/irinotecan-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-ceacd3-bispecific-antibody-ro6958688</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/buparlisib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/jak1-inhibitor-incb039110</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cbpbeta-catenin-antagonist-pri-724</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gemcitabine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-nucleolin-aptamer-as1411</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-cd73-monoclonal-antibody-medi9447</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3k-delta-inhibitor-tgr-1202</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/guadecitabine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fulvestrant</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bet-inhibitor-ro6870810</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/talazoparib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/btk-inhibitor-bgb-3111</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-pd-1-monoclonal-antibody-regn2810</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ulixertinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cdc7-inhibitor-tak-931</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/melk-inhibitor-ots167</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pd0325901</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sunitinib-malate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/acalabrutinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/beta-glucan</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-cd40-monoclonal-antibody-sea-cd40</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/enobosarm</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bicalutamide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/navitoclax</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-lag-3-monoclonal-antibody-lag525</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/regorafenib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/poziotinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ad5cmv-p53-gene</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/vactosertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trodusquemine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/vistusertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/nabiximols</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sacituzumab-govitecan</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mogamulizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mogamulizumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/crizotinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-bcma-antibody-drug-conjugate-gsk2857916</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cordycepin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bortezomib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/genistein</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mitomycin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-icos-monoclonal-antibody-medi-570</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lenalidomide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fasn-inhibitor-tvb-2640</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/braf-inhibitor-plx8394</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pevonedistat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/niclosamide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dasatinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mifepristone</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lomustine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alpha-folate-receptor-targeting-thymidylate-synthase-inhibitor-onx-0801</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/prednisone</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cabozantinib-s-malate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/navoximod</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mcl-1-inhibitor-mik665</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/l-carnitine-l-tartrate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/poly-iclc</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/p97-inhibitor-cb-5083</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/aldesleukin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dexamethasone</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/compound-kushen-injection</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alectinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lurbinectedin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/leuprolide-acetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/afatinib-dimaleate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/wild-type-reovirus</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/akt-inhibitor-mk2206</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pgg-beta-glucan</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/melphalan</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/egfrher2-inhibitor-ap32788</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cabazitaxel</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/parp-inhibitor-bgb-290</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/topotecan-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-vista-monoclonal-antibody-jnj-61610588</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fgfr-inhibitor-azd4547</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/carfilzomib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gemcitabine-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bh3-mimetic-abt-737</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/amifostine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/megestrol-acetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/seviteronel</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/magnesium-l-threonate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/exemestane</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/xentuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mcl-1-inhibitor-amg-176</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/allogeneic-natural-killer-cell-line-nk-92</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/kitpdgfr-inhibitor-dcc-2618</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/erlotinib-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gedatolisib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ny-eso-1-peptide-vaccine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fimepinostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-mutant-idh1-inhibitor-bay-1436032</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/defactinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/autologous-tumor-cell-vaccine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/betulinic-acid</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bxq-350-nanovesicle-formulation</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dinutuximab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bi-functional-alkylating-agent-val-083</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-fapinterleukin-2-fusion-protein-ro6874281</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/arsenic-trioxide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pemetrexed-disodium</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/larotrectinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dot1l-inhibitor-epz-5676</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/panobinostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/denosumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lenvatinib-mesylate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/manuka-honey</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/etoposide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pv-10</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/hyperimmune-bovine-colostrum</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-mmp-9-monoclonal-antibody-gs-5745</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/rimiducid</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bendamustine-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anetumab-ravtansine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/blinatumomab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/obinutuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gitr-agonist-medi1873</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/tesevatinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/metformin-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-cd33cd3-bite-antibody-amg-330</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gallium-ga-68-labeled-psma-11</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cdk259-inhibitor-cyc065</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/gefitinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/beetroot-juice</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-pd-1-monoclonal-antibody-tsr-042</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mutant-p53-activator-coti-2</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/multitargeted-tyrosine-kinase-inhibitor-plx3397</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/actinium-ac-225-lintuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/zoledronic-acid</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/thalidomide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ganetespib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/vemurafenib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/hif-2alpha-inhibitor-pt2385</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/annonaceous-acetogenins</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bleomycin-sulfate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/galunisertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/triapine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sipuleucel-t</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/temsirolimus</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/olaratumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-pd-1-monoclonal-antibody-jnj-63723283</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dual-alkegfr-inhibitor-ap26113</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/antineoplastic-agent-combination-sm-88</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-pd-l1-monoclonal-antibody-mdx-1105</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/wt1-protein-derived-peptide-vaccine-dsp-7888</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sting-activating-cyclic-dinucleotide-agonist-miw815</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ido1-inhibitor-khk2455</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cytarabine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3k-beta-inhibitor-gsk2636771</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fak-inhibitor-gsk2256098</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ashwagandha-root-powder-extract</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bet-inhibitor-bms-986158</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lanreotide-acetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/imiquimod</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dna-pk-inhibitor-msc2490484a</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/carmustine</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/prexasertib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pd-l1pd-l2vista-antagonist-ca-170</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ruxolitinib-phosphate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cd40-agonist-monoclonal-antibody-ro7009789</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-gitr-agonistic-monoclonal-antibody-incagn01876</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trifluridinetipiracil-hydrochloride-combination-agent-tas-102</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-lag-3-monoclonal-antibody-regn3767</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-her2-antibody-drug-conjugate-medi4276</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mdr-modulator-cbt-1</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trabectedin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-raf-kinase-inhibitor-tak-580</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/eribulin-mesylate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mdm2-inhibitor-ds-3032b</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/nimotuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fluorescent-imaging-ligand-otl38</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ceritinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ixazomib-citrate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/vorinostat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/enasidenib-mesylate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-nectin-4-antibody-drug-conjugate-asg-22ce</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/urelumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/paclitaxel-albumin-stabilized-nanoparticle-formulation</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/adenosine-a2a-receptor-antagonist-pbf-509</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/topical-fluorouracil</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/brd4-inhibitor-plx51107</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-il-8-monoclonal-antibody-humax-il8</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/antibody-drug-conjugate-sc16ld65</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/clarithromycin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ipamorelin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bet-inhibitor-gs-5829</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/montanide-isa-51-vg</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/talimogene-laherparepvec</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/mavelertinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/csf-1r-inhibitor-blz945</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/monoclonal-antibody-mga271</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/recombinant-ephb4-hsa-fusion-protein</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/apalutamide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/niraparib-tosylate-monohydrate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pladienolide-derivative-e7107</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cd40-agonist-monoclonal-antibody-cp-870893</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/idelalisib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ulocuplumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/diindolylmethane</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-c-fms-monoclonal-antibody-amg-820</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-raf-inhibitor-lxh254</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/raloxifene-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3k-inhibitor-gdc0077</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/imetelstat</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ensartinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pomalidomide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ganitumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dovitinib-lactate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c-kit-inhibitor-plx9486</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/oxidative-phosphorylation-inhibitor-iacs-010759</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bcl-2-inhibitor-bcl201</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/liposomal-cytarabine-daunorubicin-cpx-351</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sonolisib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pegylated-recombinant-human-hyaluronidase-ph20</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pegylated-recombinant-human-arginase-i-bct-100</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/goserelin-acetate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/romidepsin</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pegfilgrastim</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/onalespib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/filgrastim</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sirolimus</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/notch-signaling-pathway-inhibitor-mk0752</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ellagic-acidannona-muricata-supplement</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dna-pktor-kinase-inhibitor-cc-115</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-raf-inhibitor-ly3009120</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/leucovorin-calcium</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/hdm2-inhibitor-hdm201</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/sepantronium-bromide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bet-bromodomain-inhibitor-zen-3694</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/trebananib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/nrf2-activator-rta-408</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/anti-ctla-4-monoclonal-antibody-agen1884</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pertuzumab</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/aminolevulinic-acid-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/vinorelbine-tartrate</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pi3kmtor-inhibitor-bez235</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/nitazoxanide</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/epirubicin-hydrochloride</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bcr-abl-kinase-inhibitor-k0706</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/axitinib</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
  <url>
    <loc>https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pan-fgfr-tyrosine-kinase-inhibitor-bay1163877</loc>
	<priority>0.5</priority>
	<changefreq>weekly</changefreq>
  </url>
</urlset>